Aldoxorubicin (INNO-206) is an albumin-bound prodrug of doxorubicin, a DNA topoisomerase II inhibitor, released from albumin under acidic conditions. It has potent antitumor activity in various cancer cell lines and mouse tumor models.
Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion.
Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor.
| Topoisomerase II | Daunorubicins/Doxorubicins |
